

IX BIOPHARMA LTD.
(Incorporated in the Republic of Singapore)
(Company Registration No.: 200405621W)

**LETTER TO SHAREHOLDERS ON ALTERNATIVE ARRANGEMENTS FOR THE
EXTRAORDINARY GENERAL MEETING OF THE COMPANY TO BE HELD ON
4 SEPTEMBER 2020**

Dear Shareholders

This letter is circulated together with and forms part of iX Biopharma Ltd.'s (the "**Company**") Notice of Extraordinary General Meeting ("**EGM**") dated 11 August 2020 (the "**Notice of EGM**") and circular to shareholders dated 11 August 2020 ("**Circular**") issued by the Company in respect of the upcoming EGM scheduled to be held on Friday, 4 September 2020 at 10 a.m..

Due to the current COVID-19 restriction orders in Singapore, the board of directors (the "**Board**") wishes to inform shareholders (the "**Shareholders**") that they will not be able to attend the Extraordinary General Meeting ("**EGM**"). Instead, alternative arrangements have been put in place to allow Shareholders to participate at the EGM by (a) observing and/or listening to the EGM proceedings via live audio-visual webcast or live audio-only stream; (b) submitting questions in advance of the EGM; and/or (c) appointing the Chairman of the EGM as proxy to attend, speak and vote on their behalf at the EGM.

LIVE WEBCAST OR LIVE AUDIO STREAM

1. For Shareholders who would like to attend the EGM by electronic means, Shareholders will need to state the preference of their attendance at the EGM via LIVE WEBCAST or LIVE AUDIO STREAM, and register at <https://complete-corp.com.sg/ix-biopharma-egm>, and provide their personal particulars as follows:

- (a) Full name (for individuals) / company name (for corporates) as per CDP/SRS Account records;
- (b) National Registration Identity Card Number ("**NRIC**") or Passport Number (for individuals)/ Company Registration Number (for corporates);
- (c) Number of shares in the capital of the Company ("**Shares**") held;
- (d) Contact number; and
- (e) Email address,

no later than 10 a.m. on 1 September 2020 (being on less than seventy-two (72) hours before the time appointed for holding the EGM (the "**Registration Deadline**") to enable the Company to verify the Shareholders' status.

2. Authenticated Shareholders will receive an email confirmation by 12 p.m. on 3 September 2020 which contains either a) unique link to access the LIVE WEBCAST to view the proceedings of the EGM (via smart phones, tablets or laptop/computers); or (b) a dial-in number with a conference code to access the LIVE AUDIO STREAM (via telephone) of the EGM proceedings.
3. Shareholders **MUST NOT** forward the abovementioned unique link or dial-in number with the conference code to other persons who are not Shareholders and who are not entitled to attend. This is also to avoid technical disruptions or overload the LIVE WEBCAST and LIVE AUDIO STREAM.
4. Shareholders who would have been able to be appointed as proxies by relevant intermediaries under Section 181(1C) of the Companies Act, Cap. 50 of Singapore, such as CPF Investors and

SRS Investors (“**Investors**”), should approach their respective relevant intermediaries or agent banks to participate in the EGM via electronic means.

5. Shareholders who do not receive an email by 12 p.m. on 3 September 2020, but who have registered by the Registration Deadline should contact the Company for assistance at ixbiopharma-egm@complete-corp.com.sg, with the following details included: (a) the member’s full name; and (b) his/her/its identification/registration number.

DOCUMENTS FOR THE EGM

Documents relating to the business of the EGM, which comprises the Circular, this Notice of EGM and the Proxy Form have been published on the SGXNET and the Company’s corporate website at <https://www.ixbiopharma.com/news> on 11 August 2020.

QUESTIONS FROM SHAREHOLDERS

1. **Shareholders will not be able to ask questions during the EGM via electronic means, and therefore it is important for Shareholders to submit their questions in advance of the EGM.**
2. Shareholders may submit any questions they may have in relation to any resolution set out in the Notice of EGM by 10 a.m. on 1 September 2020 (being no less than seventy-two (72) hours before the time appointed for holding the EGM:
 - (a) via the registration website at <https://complete-corp.com.sg/ix-biopharma-egm>;
 - (b) by email to ixbiopharma-egm@complete-corp.com.sg; or
 - (c) in hard copy by sending personally or by post and lodging the same at the office of the Company’s principal place of business at 1 Kim Seng Promenade, #14-01 Great World City East Tower, Singapore 237994.

Shareholders submitting questions are required to provide their particulars as follows:

- (a) Full name (for individuals) / company name (for corporates) as per CDP/SRS Account records;
 - (b) National Registration Identity Card Number (“**NRIC**”) or Passport Number (for individuals)/ Company Registration Number (for corporates);
 - (c) Number of shares in the capital of the Company (“**Shares**”) held;
 - (d) Contact Number; and
 - (e) Email Address.
3. The Company will provide responses to substantial queries and relevant comments from Shareholders relating to the agenda of the EGM prior to, or at, the EGM via electronic means. The Company will address any subsequent clarifications sought, or follow-up questions, prior to, or at the EGM in respect of substantial queries and relevant comments. The responses from the Board and management of the Company shall thereafter be published on SGXNET and the Company’s corporate website at <https://www.ixbiopharma.com/news>, together with the minutes of the EGM, within one (1) month after the conclusion of the EGM.
 4. Shareholders, who would have been able to be appointed as proxies by relevant intermediaries under Section 181(1C) of the Companies Act, Cap. 50 of Singapore, such as CPF Investors and SRS Investors (“**Investors**”), should approach their respective relevant intermediaries or agent banks, to submit their questions in relation to any resolution set out in the Notice of EGM prior to the EGM and have their substantial queries and relevant comments answered.

PROXY VOTING

1. **Voting at the EGM is by proxy ONLY. Please note that Shareholders will not be able to vote through the LIVE WEBCAST and LIVE AUDIO STREAM and can any vote with their proxy forms which are required to be submitted in accordance with the following paragraphs.**

2. Shareholders who wish to vote on the resolution at the EGM must appoint the Chairman of the EGM as their proxy by completing the respective Proxy Form for the EGM. Shareholders appointing the Chairman of the Meeting as proxy must give specific instructions as to his/her/its manner of voting, or abstentions from voting, in the proxy form, failing which the appointment will be treated as invalid.
3. The instrument appointing the Chairman of the EGM as proxy (the **"Proxy Form"**) together with power of attorney of other authority (if any) under which it is signed, or a notarial certified copy, must be submitted to the Company in the following manner:
 - (a) if submitted by post, be deposited at the office of the Company's Share Registrar, Tricor Barbinder Share Registration Services at 80 Robinson Road, #11-02, Singapore 068898; or
 - (b) if submitted electronically, be submitted via email to the Company at ixbiopharma-egm@complete-corp.com.sg,

in any case, not later than 10 a.m. on 1 September 2020 (being 72 hours before the time fixed for the EGM) and in default the Proxy Form for the EGM shall not be treated as valid.

4. **In view of the current Covid-19 situation and the related safe distancing measures which may make it difficult for members to submit completed Proxy Forms by post, members are strongly encouraged to submit completed Proxy Forms electronically via email as early as possible, to enable your vote(s) to be counted, and to follow all government guidance and requirements.**
5. CPF Investors and SRS Investors who wish to appoint the Chairman of the EGM as their proxy should approach their respective agent banks to submit their votes no later than 10 a.m. on 26 August 2020, being seven (7) working days before the date of the EGM. CPF Investors and SRS Investors should not directly appoint the Chairman as proxy to direct the vote. The Proxy Form is not valid for use by CPF and SRS Investors and shall be ineffective for all intents and purposes if used or purported to be used by them.

As the COVID-19 situation continues to evolve, the Company is closely monitoring the situation, including any precautionary measures which may be required or recommended by government agencies to minimise the risk of community spread of COVID-19. **Shareholders should note that the Company may be required (including at short notice) to make further changes to its EGM arrangements as the situation evolves, and Shareholders are advised to keep abreast of any such changes as may be announced by the Company as may be made from time to time on SGXNET.**

BY ORDER OF THE BOARD

Lee Wei Hsiung / Wang Shin Lin, Adeline
Company Secretaries
11 August 2020

This notice has been prepared by the Company and its contents have been reviewed by the Company's sponsor, CIMB Bank Berhad, Singapore Branch ("Sponsor") in accordance with Rule 226(2)(b) of the Catalist Rules. The Sponsor has not verified the contents of this notice.

This Notice has not been examined or approved by the SGX-ST and the SGX-ST assume no responsibility for the contents of this notice, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this notice.

The contact person for the Sponsor is Mr. Yee Chia Hsing, Head, Catalist. The contact particulars are 50 Raffles Place, #09-01 Singapore Land Tower, Singapore 048623, telephone: (65) 6337-5115.